Abstract
Abstract
Introduction
The WHO 2020 classification of tumors of the female genital tract has adopted the dualistic classification of cervical squamous and adenocarcinoma into HPV–HPV-associated and HPV–HPV-independent types. However, the separate discussion on 'rare' varieties of cervical cancer is significant as it allows us to delve into their risk factors and natural course of disease and define any alternative treatment strategies to improve outcomes.
Objectives
To estimate the factors associated with histologically proven rare malignant tumors of the cervix and the overall survival of rare malignant cervical tumors in a tertiary care institute of Northeast India (NEI).
Methods
Our tertiary care institute in Northeast India, a region with unique healthcare challenges, including a high incidence of cervical cancers, conducted this retrospective study from 01/01/2018 to 31/12/2022. It excluded patients with incomplete records, squamous and adenocarcinoma histology, and metastatic cancer to the cervix. We collected demographic and survival data and performed survival analysis using SPSS 29.0.
Results
Out of 2367 diagnosed cervical cancer patients, 45 patients (1.9%) were diagnosed with rare cancer. Adenosquamous (0.7%) was the leading histology, followed by small cell NET (0.59%) and clear cell carcinoma (0.33%) in rare cervical cancer. Bleeding per vaginum was the presenting symptom in 91%. More than 80% of patients had a short duration of illness (< 6 months). Stage III (42%), followed by Stage II (27%), Stage IV (21%), and Stage I (10%) were presenting stages. A final diagnosis in 72% of histology required immunohistochemistry (IHC). Most of the patient (65%) did not complete their treatment.
Conclusion
This study's findings underscore the need for collective efforts in studying rare cancers, which can significantly enhance treatment strategies and improve the overall prognosis and quality of life for individuals affected.
Funder
Dr. B Borooah Cancer Institute
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Rajappa S, Singh M, Uehara R, Schachterle SE, Setia S. Cancer incidence and mortality trends in Asia based on regions and human development index levels: an analyses from GLOBOCAN 2020. Curr Med Res Opin. 2023;39(8):1127–37.
2. Lee Y, Bae H, Kim HS. Endocervical adenocarcinoma: comprehensive histological review and re-classification of 123 consecutive cases according to the updated world health organization classification of female genital tumors. Anticancer Res. 2022;42(9):4627–39.
3. Höhn AK, Brambs CE, Hiller GG, May D, Schmoeckel E, Horn LC. 2020 WHO classification of female genital tumors. Geburtshilfe Frauenheilkd. 2021;81(10):1145–53.
4. Dukes MNG. Priority medicines and the world. Bull World Health Organ. 2005;83:324–324.
5. Mailankody S, Bajpai J, Budukh A, Swaminathan R, Dikshit R, Dhimal M, et al. Epidemiology of rare cancers in India and South Asian countries – remembering the forgotten. The Lancet Regional Health - Southeast Asia [Internet]. 2023 May 1 [cited 2024 Jan 15];12. Available from: https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(23)00028-8/fulltext